HIGH-GRADE ENDOMETRIOID OVARIAN CANCER
Clinical trials for HIGH-GRADE ENDOMETRIOID OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE ENDOMETRIOID OVARIAN CANCER trials appear
Sign up with your email to follow new studies for HIGH-GRADE ENDOMETRIOID OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to outsmart resistant ovarian cancer
Disease control OngoingThis Phase 2 trial tests two experimental drug combinations in 63 women with a specific type of ovarian cancer (BRCA-mutant or HRD-positive) that has worsened after prior PARP inhibitor treatment. Participants receive either tuvusertib plus niraparib or tuvusertib plus larteserti…
Matched conditions: HIGH-GRADE ENDOMETRIOID OVARIAN CANCER
Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug may delay return of ovarian cancer
Disease control OngoingThis study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer whose tumors shrank or disappeared after platinum-based chemotherapy. The goal is to see if taking this drug daily can delay the cancer from coming back. The tri…
Matched conditions: HIGH-GRADE ENDOMETRIOID OVARIAN CANCER
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for ovarian cancer: drug may delay return of disease
Disease control OngoingThis study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation. Participants have already responded well to initial chemotherapy. The trial compares olaparib to a placebo to see if it extends the ti…
Matched conditions: HIGH-GRADE ENDOMETRIOID OVARIAN CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC